Morgan Stanley assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a report published on Wednesday morning, Marketbeat reports. The firm issued an overweight rating and a $10.00 price objective on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright restated a buy rating and issued a $18.00 price target on shares of Nabriva Therapeutics in a report on Tuesday, September 19th. Needham & Company LLC restated a buy rating and issued a $18.00 price target (up previously from $15.00) on shares of Nabriva Therapeutics in a report on Tuesday, September 19th. Finally, Zacks Investment Research cut Nabriva Therapeutics from a buy rating to a hold rating in a report on Saturday, November 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. Nabriva Therapeutics currently has a consensus rating of Buy and a consensus price target of $17.53.

Nabriva Therapeutics (NASDAQ:NBRV) traded up $0.06 on Wednesday, hitting $6.59. The company had a trading volume of 205,608 shares, compared to its average volume of 145,593. The firm has a market cap of $241.79, a PE ratio of -2.69 and a beta of 1.54. Nabriva Therapeutics has a 1-year low of $4.75 and a 1-year high of $14.10.

Nabriva Therapeutics (NASDAQ:NBRV) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.07). Nabriva Therapeutics had a negative return on equity of 80.69% and a negative net margin of 985.30%. equities research analysts forecast that Nabriva Therapeutics will post -2.6 earnings per share for the current year.

Large investors have recently made changes to their positions in the business. Rubric Capital Management LP acquired a new stake in Nabriva Therapeutics during the 3rd quarter valued at $2,457,000. Pura Vida Investments LLC acquired a new stake in Nabriva Therapeutics during the 3rd quarter valued at $3,481,000. Alyeska Investment Group L.P. acquired a new stake in Nabriva Therapeutics during the 3rd quarter valued at $5,724,000. Perceptive Advisors LLC acquired a new stake in Nabriva Therapeutics during the 3rd quarter valued at $431,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Nabriva Therapeutics during the 3rd quarter valued at $348,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Nabriva Therapeutics (NBRV) Now Covered by Morgan Stanley” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://theolympiareport.com/2018/01/21/nabriva-therapeutics-nbrv-now-covered-by-morgan-stanley.html.

About Nabriva Therapeutics

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.